02509.HK
Qyuns Therapeutics Co., Ltd.
HKSE · Healthcare · Biotechnology · CN
HKD 16.44
−1.73%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.0B | 786.1M | 158.8M | 14.8M | 9.7M |
| Cost of Revenue | 116.4M | 121.4M | 66.6M | 35.7M | 35.5M |
| Gross Profit | 908.1M | 664.7M | 92.2M | 14.8M | (25.9M) |
| Operating Expenses | |||||
| R&D Expense | 200.0M | 239.2M | 334.3M | 364.4M | 270.7M |
| SG&A Expense | 129.5M | 130.4M | 116.9M | 164.6M | 82.0M |
| General & Admin Expense | 83.2M | 99.8M | 115.9M | 164.6M | 76.6M |
| Selling & Marketing Expense | 41.3M | 30.6M | 926.0K | — | 5.4M |
| Other Expenses | 20.1M | (24.7M) | (32.6M) | (24.5M) | (40.1M) |
| Total Operating Expenses | 349.6M | 344.9M | 418.6M | 504.5M | 352.7M |
| Cost and Expenses | 466.0M | 466.3M | 485.2M | 504.5M | 303.4M |
| Operating Income (EBIT) | 558.5M | 319.7M | (326.4M) | (504.5M) | (293.7M) |
| Non-Operating | |||||
| Interest Income | — | 8.3M | 7.8M | 4.5M | 4.2M |
| Interest Expense | — | 21.6M | 23.4M | 16.8M | 18.7M |
| Net Interest Income | (4.6M) | (13.3M) | (15.6M) | (12.4M) | (14.5M) |
| Other Non-Op Income/Expense | (21.6M) | (20.3M) | (23.4M) | (16.8M) | (18.7M) |
| Non-Operating Income (excl Interest) | 6.6M | — | 15.9M | 9.7M | 30.5M |
| EBT (Pre-Tax Income) | 536.9M | 299.4M | (349.8M) | (521.3M) | (312.4M) |
| Income Tax Expense | 73.0K | 71.1K | (73.0K) | (73.0K) | (73.0K) |
| Bottom Line | |||||
| Net Income | 546.1M | 306.3M | (335.6M) | (507.7M) | (298.2M) |
| Earnings from Cont. Ops | 536.9M | 299.3M | (349.7M) | (521.3M) | (312.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 546.1M | 306.3M | (335.6M) | (507.7M) | (298.2M) |
| Per Share | |||||
| Basic EPS | HK$2.42 | HK$1.37 | (HK$1.53) | (HK$2.47) | (HK$1.56) |
| Diluted EPS | HK$2.42 | HK$1.37 | (HK$1.53) | (HK$2.47) | (HK$1.56) |
| Revenue Per Share | HK$4.56 | HK$3.51 | HK$0.72 | HK$0.07 | HK$0.04 |
| Shares | |||||
| Basic Shares Outstanding | 224.5M | 223.7M | 219.4M | 205.7M | 222.1M |
| Diluted Shares Outstanding | 224.5M | 223.7M | 219.4M | 205.7M | 222.1M |
| Profitability Metrics | |||||
| EBITDA | 581.3M | 351.0M | (311.8M) | (484.1M) | (295.5M) |
| D&A | 29.5M | 31.3M | 30.5M | 32.3M | 28.6M |
| EBIT | 551.9M | 319.7M | (342.3M) | (514.2M) | (324.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026